Vaxcyte (PCVX) Interest & Investment Income (2019 - 2026)

Vaxcyte (PCVX) has reported Interest & Investment Income for 8 consecutive years, with $26.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest & Investment Income fell 19.2% year-over-year to $26.6 million; the TTM figure through Mar 2026 stood at $113.4 million (down 6.49% YoY), while the FY2025 annual figure was $119.7 million, up 8.84% from the prior year.
• Interest & Investment Income rose to $26.6 million in Q1 2026 per PCVX's latest filing, from $26.5 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $36.5 million in Q4 2024 and bottomed at -$592000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $19.2 million across 5 years, with a median of $21.7 million in 2024.
• On a YoY basis, Interest & Investment Income climbed as much as 6600.0% in 2022 and fell as far as 1070.49% in 2022.
• Vaxcyte's Interest & Investment Income stood at $6.6 million in 2022, then surged by 164.86% to $17.6 million in 2023, then soared by 107.53% to $36.5 million in 2024, then dropped by 27.45% to $26.5 million in 2025, then rose by 0.6% to $26.6 million in 2026.
• Business Quant data shows PCVX's Interest & Investment Income at $26.6 million in Q1 2026, $26.5 million in Q4 2025, and $29.3 million in Q3 2025.